ABT

SEC source: 0001415889-25-023588 · form4-09032025_090946.xml · nonDerivative · entry 1

MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,982

SEC source: 0001415889-25-021451 · form4-08112025_090800.xml · nonDerivative · entry 1

Boudreau Philip P · CIK 0001805099 · EVP AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,003

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.551 to $134.58, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-25-018725 · form4-07012025_080744.xml · nonDerivative · entry 1

Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,609

SEC source: 0001415889-25-018730 · form4-07012025_090745.xml · derivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,655

Underlying: Common Shares · 242 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-018729 · form4-07012025_090737.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,195

Underlying: Common Shares · 57 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-018731 · form4-07012025_090714.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Shares · 271 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-018736 · form4-07012025_090714.xml · derivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,315

Underlying: Common Shares · 282 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-018721 · form4-07012025_080750.xml · derivative · entry 2

Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,680

Underlying: Common Shares · 14,680 shares

Expires 2035-06-26

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,893 on June 27, 2026, 4,893 on June 27, 2027, and 4,894 on June 27, 2028.

SEC source: 0001415889-25-018721 · form4-07012025_080750.xml · nonDerivative · entry 1

Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,226

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-25-011837 · form4-05022025_090502.xml · nonDerivative · entry 1

Blount Sally E. · CIK 0001537286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,058

SEC source: 0001415889-25-011510 · form4-04292025_090442.xml · nonDerivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,798

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011516 · form4-04292025_090438.xml · nonDerivative · entry 1

Babineaux-Fontenot Claire · CIK 0001736637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,317

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011518 · form4-04292025_090438.xml · nonDerivative · entry 1

Blount Sally E. · CIK 0001537286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,658

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011520 · form4-04292025_090456.xml · nonDerivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,919

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011521 · form4-04292025_090442.xml · nonDerivative · entry 1

Kumbier Michelle · CIK 0001640036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,714

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011522 · form4-04292025_090450.xml · nonDerivative · entry 1

McDew Darren W · CIK 0001787479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,392

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011525 · form4-04292025_090434.xml · derivative · entry 2

McKinstry Nancy · CIK 0001294731 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,465

Underlying: Common Shares · 1,465 shares

Expires 2035-04-24

F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-011525 · form4-04292025_090434.xml · nonDerivative · entry 1

McKinstry Nancy · CIK 0001294731 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,724

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011526 · form4-04292025_100454.xml · derivative · entry 2

O'Grady Michael · CIK 0001527742 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,769

Underlying: Common Shares · 3,769 shares

Expires 2035-04-24

F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-011526 · form4-04292025_100454.xml · nonDerivative · entry 1

O'Grady Michael · CIK 0001527742 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,317

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011527 · form4-04292025_100427.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,478

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011528 · form4-04292025_100405.xml · derivative · entry 3

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,516

Underlying: Common Shares · 4,516 shares

Expires 2035-04-24

F3 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-011528 · form4-04292025_100405.xml · nonDerivative · entry 1

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,728,817

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-011531 · form4-04292025_100425.xml · nonDerivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,033

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-009706 · form4-04022025_090440.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,093

Underlying: Common Shares · 59 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-009731 · form4-04022025_090428.xml · derivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,393

Underlying: Common Shares · 248 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-009737 · form4-04022025_090402.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,957

Underlying: Common Shares · 265 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-009742 · form4-04022025_090452.xml · derivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,979

Underlying: Common Shares · 277 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-007453 · form4-03072025_110313.xml · derivative · entry 6

Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common shares · 200 shares

Expires 2029-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-007453 · form4-03072025_110313.xml · nonDerivative · entry 4

Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,928

SEC source: 0001415889-25-007453 · form4-03072025_110313.xml · nonDerivative · entry 3

Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,128

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-007453 · form4-03072025_110313.xml · derivative · entry 5

Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200

Underlying: Common shares · 91,167 shares

Expires 2029-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-007453 · form4-03072025_110313.xml · nonDerivative · entry 2

Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,928

SEC source: 0001415889-25-007453 · form4-03072025_110313.xml · nonDerivative · entry 1

Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,095

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006768 · form4-03052025_120309.xml · nonDerivative · entry 2

MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,061

SEC source: 0001415889-25-006786 · form4-03052025_120337.xml · nonDerivative · entry 2

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,583

SEC source: 0001415889-25-006788 · form4-03052025_120335.xml · nonDerivative · entry 2

Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,878

SEC source: 0001415889-25-006794 · form4-03052025_010316.xml · nonDerivative · entry 1

Shroff Eric · CIK 0002058129 · Senior Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,970

SEC source: 0001415889-25-006798 · form4-03052025_010318.xml · nonDerivative · entry 2

Wainer Andrea F · CIK 0001778070 · RETIRED EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,381

SEC source: 0001415889-25-006738 · form4-03052025_120336.xml · nonDerivative · entry 1

ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT, GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,899

SEC source: 0001415889-25-006741 · form4-03052025_120306.xml · nonDerivative · entry 1

Boudreau Philip P · CIK 0001805099 · EVP AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,553

SEC source: 0001415889-25-006743 · form4-03052025_120339.xml · nonDerivative · entry 1

Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,928

SEC source: 0001415889-25-006755 · form4-03052025_120328.xml · nonDerivative · entry 1

Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,305

SEC source: 0001415889-25-006768 · form4-03052025_120309.xml · nonDerivative · entry 1

MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,623

SEC source: 0001415889-25-006786 · form4-03052025_120337.xml · nonDerivative · entry 1

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,374

SEC source: 0001415889-25-006788 · form4-03052025_120335.xml · nonDerivative · entry 1

Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,989

SEC source: 0001415889-25-006789 · form4-03052025_120314.xml · nonDerivative · entry 1

Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,769

SEC source: 0001415889-25-006798 · form4-03052025_010318.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · RETIRED EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,330

SEC source: 0001415889-25-005885 · form4-02272025_100252.xml · derivative · entry 3

Boudreau Philip P · CIK 0001805099 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,783

Underlying: Common Shares · 83,783 shares

Expires 2035-02-24

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,927 on February 25, 2026, 27,928 on February 25, 2027, and 27,928 on February 25, 2028.

SEC source: 0001415889-25-005885 · form4-02272025_100252.xml · nonDerivative · entry 1

Boudreau Philip P · CIK 0001805099 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,461

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.